Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02632175 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT02632175 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 59 participants.
The verdict
NCT02632175, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.
Interventions
- BIOLOGICAL Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-11-26 |
| Est. Completion | 2025-04-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02632175
The ClinicalTrials.gov registry entry for NCT02632175 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adalimumab is the first listed.
NCT02632175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02632175 about?
NCT02632175 is a clinical study titled "Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis". This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.
What is the current status of trial NCT02632175?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2015-11-26. Estimated completion is 2025-04-08.
What interventions are being tested in trial NCT02632175?
The interventions under investigation include: Adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02632175?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.